SAN FRANCISCO, Nov. 13 – Exelixis on Tuesday posted third-quarter revenues of $11.9 million versus $6.1 for the same quarter a year ago, the company announced.

The South San Francisco-based company attributed the revenue rise to new collaborations with Bristol-Myers Squibb and Protein Design Labs.

Exelixis reported a net loss of $13.4 million, or 28 cents per share for the third quarter of 2001, compared to a net loss of $5.5 million, or 13 cents per share for the third quarter of 2000. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.